



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAFAMIDIS

Generic	Brand	HICL	GCN	Exception/Other
TAFAMIDIS MEGLUMINE	VYNDAQEL	41631		
TAFAMIDIS	VYNDAMAX	45729		

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a documented diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) as confirmed by **ONE** of the following?
  - Bone scan (scintigraphy) strongly positive for myocardial uptake of 99mTcPYP/DPD  
*(Note: Strongly positive defined as heart to contralateral lung [H/CL] ratio of at least 1.5 or Grade 2 or greater localization to the heart using the Perugini Grade 1-3 scoring system)*
  - Biopsy of tissue of affected organ(s) (cardiac and possibly non-cardiac sites) to confirm amyloid presence **AND** chemical typing to confirm presence of transthyretin (TTR) protein

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or given in consultation with a cardiologist, transthyretin amyloidosis (ATTR) specialist, or medical geneticist
  - The patient has New York Heart Association (NYHA) class I, II, or III heart failure

If yes, **approve for 12 months for both of the following drugs:**

- **VynDAQel (tafamidis meglumine): Approve by HICL (41631) with a quantity limit of #4 per day.**
- **Vyndamax (tafamidis): Approve by HICL (45729) with a quantity limit of #1 per day.**

**APPROVAL TEXT:** Renewal requires the physician attestation that the patient has not progressed to New York Heart Association (NYHA) Class IV heart failure.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAFAMIDIS

INITIAL CRITERIA (CONTINUED)

**INITIAL DENIAL TEXT:** The guideline named **TAFAMIDIS (Vyndaqel, Vyndamax)** requires a documented diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). In addition, the following criteria must be met.

- Diagnosis confirmed by ONE of the following:
  - Bone scan (scintigraphy) strongly positive for myocardial uptake of 99mTcPYP/DPD (**Note:** Strongly positive defined as heart to contralateral lung [H/CL] ratio of at least 1.5 or Grade 2 or greater localization to the heart using the Perugini Grade 1-3 scoring system)
  - Biopsy of tissue of affected organ(s) (cardiac and possibly non-cardiac sites) to confirm amyloid presence **AND** chemical typing to confirm presence of transthyretin (TTR) protein
- The patient is 18 years of age or older
- Therapy is prescribed by or given in consultation with a cardiologist, transthyretin amyloidosis (ATTR) specialist, or medical geneticist
- The patient has New York Heart Association (NYHA) class I, II or III heart failure

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) **AND** meet the following criterion?
  - Physician attestation that the patient has not progressed to New York Heart Association (NYHA) Class IV heart failure

If yes, **approve for 12 months for both of the following drugs:**

- **Vyndaqel (tafamidis meglumine): Approve by HICL (41631) with a quantity limit of #4 per day.**
- **Vyndamax (tafamidis): Approve by HICL (45729) with a quantity limit of #1 per day.**

If no, do not approve.

**RENEWAL DENIAL TEXT:** The guideline named **TAFAMIDIS (Vyndaqel, Vyndamax)** requires a diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). In addition, the following must be met.

- Physician attestation that the patient has not progressed to New York Heart Association (NYHA) Class IV heart failure

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

TAFAMIDIS

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vyndaqel and Vyndamax.

**REFERENCES**

- Vyndaqel [Prescribing Information]. New York, NY: Pfizer Inc.; May 2019.
- Vyndamax [Prescribing Information]. New York, NY: Pfizer Inc.; August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/19

Created: 05/19

Client Approval: 09/19

P&T Approval: 04/19